Dupixent (dupilumab) Lawsuit
Levin Sedran & Berman LLP is investigating potential cases regarding the anti-inflammatory drug Dupixent (dupilumab) and its reported connection to a specific cancer called cutaneous T-cell lymphoma (CTCL). Doctors published a retrospective cohort study in the Journal of the American Academy of Dermatology that associated Dupixent with an increased risk of CTCL (see study).
Contact Us For A Free Case Review
Call 877-882-1011 or Email UsOr Continue reading.
IMPORTANT: The information provided on this website is not a substitute for professional medical advice. If you are currently experiencing any side effect from Dupixent, contact a healthcare professional immediately. Do not stop taking prescription medications like Dupixent without talking to your doctor or healthcare provider.
Are You Interested in a Dupixent Lawsuit?
If you or a loved one has been diagnosed with CTCL or had a prior CTCL diagnosis worsen after taking the drug Dupixent, you may be able to seek financial compensation through a lawsuit. Our Dupixent attorneys are currently evaluating lawsuits for diagnosed CTCL.
If you have questions about a potential Dupixent lawsuit, contact our attorneys today for a free case evaluation. We take pride in providing honest case evaluations and there is no obligation to sign with us if you call.
Call Us To Speak With a Dupixent attorneyCONTACT US TODAY
As an experienced, professional team, Levin, Sedran & Berman LLP provide superior representation in all cases.
What Is Dupixent (dupilumab)?
Dupixent is an anti-inflammatory injectable drug prescribed to patients with moderate-to-severe atopic dermatitis (AD), among other medical conditions. It is marketed by Regeneron Pharmaceuticals and Sanofi Genzyme.
What is Cutaneous T-Cell Lymphoma (CTCL)?
Cutaneous T-Cell Lymphoma is a rare type of blood cancer that affects white blood cells called T cells (also called T lymphocytes), causing them to attack the skin. This reaction can cause rashes, scaly round patches, or other growths on the skin.